2017
LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts).
Burtness B, Haddad R, Dinis J, Trigo Perez J, Yokota T, Viana L, Romanov I, Vermorken J, Bourhis J, Tahara M, Segalla J, Psyrri A, Vasilevskaya I, Nangia C, Chaves-Conde M, Wang B, Gibson N, Ehrnrooth E, Harrington K, Cohen E. LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts). Journal Of Clinical Oncology 2017, 35: 6001-6001. DOI: 10.1200/jco.2017.35.15_suppl.6001.Peer-Reviewed Original ResearchDisease-free survivalPhase III trialsIII trialsEGFR inhibitionMedian disease-free survivalRecurrent/metastatic diseaseErbB family blocker afatinibPre-planned interim analysisECOG PS 0Median treatment durationSquamous cell cancerDefinitive chemoradiationECOG PSEligible ptsAdvanced HNSCCConcurrent cisplatinN2 diseasePrimary endpointAdjuvant therapyMetastatic diseasePS 0Complete responseDisease recurrenceMedian ageNodal stage
2012
59IN Strategies to Optimize EGFR Therapies
Burtness B. 59IN Strategies to Optimize EGFR Therapies. Annals Of Oncology 2012, 23: ix42. DOI: 10.1016/s0923-7534(20)32673-9.Peer-Reviewed Original ResearchRecurrent/metastatic diseaseCombination of cetuximabCetuximab resistanceKinase inhibitorsMetastatic diseaseNeck cancerNuclear translocationInternational phase III trialReceptor tyrosine kinasesPhase III trialsSquamous cell carcinomaAugmentation of responsesDe novo resistanceH-ras mutationsMonoclonal antibody cetuximabTyrosine kinase inhibitorsK-ras mutationsFirst kinase inhibitorEpidermal growth factor receptorBristol-Myers SquibbGrowth factor receptorAdvanced headEGFR/HER2III trialsOral agents
2009
Phase II study of pemetrexed (P) and gemcitabine (G) in patients with advanced head and neck cancer (SCCHN)
Mehra R, Sherman E, Ruth K, Litwin S, Sylvester J, Tuttle H, Burtness B, Cohen R, Langer C. Phase II study of pemetrexed (P) and gemcitabine (G) in patients with advanced head and neck cancer (SCCHN). Journal Of Clinical Oncology 2009, 27: 6052-6052. DOI: 10.1200/jco.2009.27.15_suppl.6052.Peer-Reviewed Original ResearchPhase II studyResponse rateII studyOverall survivalMetastatic squamous cell cancerRecurrent/metastatic SCCHNRecurrent/metastatic diseaseStage 1Adequate bone marrowGrade 4 anemiaGrade 3 toxicityMedian overall survivalSquamous cell cancerLack of efficacyAdvanced HNSCCKarnofsky PSLA-SCCHNMetastatic SCCHNPrior therapyUnconfirmed PRAlternative regimenDefinitive therapyPrimary endpointRecurrent diseaseSecondary endpoints
2008
The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.
Mehra R, Cohen RB, Burtness BA. The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clinical Advances In Hematology And Oncology 2008, 6: 742-50. PMID: 18997665, PMCID: PMC2745918.Peer-Reviewed Original ResearchConceptsRecurrent/metastatic diseaseRole of cetuximabSquamous cell carcinomaTreatment of HNSCCEpidermal growth factor receptorMetastatic diseaseCell carcinomaFirst-line regimenStandard of careGrowth factor receptorSurvival benefitSignificant morbidityCurable diseaseClinical trialsSingle agentDrug AdministrationCetuximabEGFR inhibitorsHNSCCBeneficial effectsDiseaseMonoclonal antibodiesFactor receptorCarcinomaFollowing review